Skip to main content

Table 3 Rejection pathology and rescue treatments in the patients who experienced biopsy proven rejection within 1 year after transplantation

From: Transplant outcomes in positive complement-dependent cytotoxicity- versus flow cytometry-crossmatch kidney transplant recipients after successful desensitization: a retrospective study

Variables

CDC − FC−

(n = 42)

CDC − FC+

(n = 11)

CDC + FC+

(n = 8)

P

Median time to BPAR (days)

42 (11–109)

9 (5–31)

14 (5–38)

0.035

Type of acute rejection

   

< 0.001

 ABMR

18 (42.9%)

10 (90.9%)

8 (100%)

 

 TCMR

24 (57.1%)

1 (9.1%)

0 (0%)

 

Rescue treatment

   

< 0.001

 Steroid pulse only

16 (38.1%)

0

2 (25.0%)

 

 Steroid pulse + ATG

7 (16.7%)

0

0

 

 PP/IVIG

19 (45.2%)

8 (72.7%)

1 (12.5%)

 

 PP/IVIG + bortezomib

0

3 (27.3%)

5 (62.5%)

 
  1. ABMR Antibody-mediated graft rejection, ATG Anti-thymocyte globulin, BPAR Biopsy-proven rejection, CDC Complement dependent cytotoxicity, FC Flow cytometry, IVIG Intravenous immunoglobulin, PP Plasmapheresis, TCMR T-cell medicated rejection